论文部分内容阅读
目的:观察人基因重组红细胞生成素(rHuEPO)对慢性肾功能衰竭未透析患者贫血的疗效和肾功能的影响.方法:39例患者rHuEPO起始剂量100IU/kg,每周3次sc,观察5～30mo.结果:rHuEPO治疗20wk后所有患者贫血明显纠正,平均Hct由(18±2)%上升至(32±3)%(P<0.001),生活质量显著提高.治疗早期Hct上升幅度尿毒症未透析组显著低于氮质血症组.尿毒症未透析组rHuEPO维持剂量显著高于氮质血症组.分别为(150±57.7)和(275.0±42.5)IU·kg~(-1)·wk~(-1)(P<0.01).以血Cr倒数为指标,治疗期间患者肾功能恶化速度与治疗前无显著差别.治疗期间50%患者BP升高.结论:rHuEPO能有效纠正慢性肾功能衰竭未透析患者贫血,不加速肾功能恶化.
Objective: To observe the effect of recombinant human erythropoietin (rHuEPO) on anemia and renal function in patients with chronic renal failure without hemodialysis.Methods: The rHuEPO starting dose was 100IU / kg in 39 patients, sc ~ 30mo.Results: After 20 weeks of rHuEPO treatment, the anemia of all the patients was corrected obviously, the average Hct increased from (18 ± 2)% to (32 ± 3)% (P <0.001), and the quality of life improved significantly. In the non-dialysis group, the rHuEPO maintenance dose was significantly higher in the non-dialysis group than in the azotemia group (150 ± 57.7 and 275.0 ± 42.5 IU · kg -1, respectively) · Wk ~ (-1) (P <0.01) .With the count of blood Cr as an index, there was no significant difference in the rate of deterioration of renal function between the two groups before treatment and in 50% of patients during treatment.Conclusion: rHuEPO can effectively correct chronic Patients with renal failure without dialysis anemia, does not accelerate the deterioration of renal function.